References
- Callen JP. Immunomodulators. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology Vol. 2, 2nd ed. Philadelphia, PA: Mosby, 2008; 1973–1990.
- Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757–790.
- Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181–1192.
- Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159:1217–1228.
- Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes 2007;14:32–36.
- Dobec M, Bossart W, Kaeppeli F, Mueller-Schoop J. Serology and serum DNA detection in shingles. Swiss Med Wkly 2008;138:47–51.
- Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 2008;80:467–477.
- Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003;26:277–89; discussion 291.
- Choi HJ, Kim MY, Kim HO, Park YM. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006;45:999–1000.
- Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Jama 2009;301:737–744.